Blood-based biomarkers of frailty in older patients with cancer.

IF 1.9 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Current Opinion in Supportive and Palliative Care Pub Date : 2025-03-01 Epub Date: 2025-01-30 DOI:10.1097/SPC.0000000000000747

Baran Akagunduz, Yakup Ergün, Dig dem Dog An Akagündüz, Nergis Akbas, Dilara Akagündüz, Aziz Karaog Lu, Pinar Soysal

{"title":"Blood-based biomarkers of frailty in older patients with cancer.","authors":"Baran Akagunduz, Yakup Ergün, Dig dem Dog An Akagündüz, Nergis Akbas, Dilara Akagündüz, Aziz Karaog Lu, Pinar Soysal","doi":"10.1097/SPC.0000000000000747","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review aims to evaluate the current evidence on blood-based biomarkers for frailty detection in older cancer patients. It explores the potential of various biomarkers, including inflammatory markers and microRNAs (miRNAs), to serve as indicators of frailty and examines the limitations of existing studies. The review also highlights the need for further research to validate these biomarkers and improve their clinical applicability.Recent findings: Recent studies have examined blood biomarkers associated with frailty in older cancer patients. Findings suggest that elevated granulocyte levels and lower macrophage-derived stem cells and regulatory T cells are linked to frailty. Inflammatory biomarkers such as interleukin-6 and specific miRNAs, as well as higher neutrophil-to-lymphocyte ratios, have also been identified as potential indicators of frailty. While these biomarkers show promise, no single marker has proven sufficient, and combining them may improve frailty detection. Further research is needed to validate their clinical usefulness in this population.Summary: Blood-based biomarkers show potential for detecting frailty in older patients with cancer, but further research is needed, particularly beyond an inflammatory focus and with more robust study designs.","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":"19 1","pages":"25-32"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Supportive and Palliative Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/SPC.0000000000000747","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review aims to evaluate the current evidence on blood-based biomarkers for frailty detection in older cancer patients. It explores the potential of various biomarkers, including inflammatory markers and microRNAs (miRNAs), to serve as indicators of frailty and examines the limitations of existing studies. The review also highlights the need for further research to validate these biomarkers and improve their clinical applicability.

Recent findings: Recent studies have examined blood biomarkers associated with frailty in older cancer patients. Findings suggest that elevated granulocyte levels and lower macrophage-derived stem cells and regulatory T cells are linked to frailty. Inflammatory biomarkers such as interleukin-6 and specific miRNAs, as well as higher neutrophil-to-lymphocyte ratios, have also been identified as potential indicators of frailty. While these biomarkers show promise, no single marker has proven sufficient, and combining them may improve frailty detection. Further research is needed to validate their clinical usefulness in this population.

Summary: Blood-based biomarkers show potential for detecting frailty in older patients with cancer, but further research is needed, particularly beyond an inflammatory focus and with more robust study designs.

查看原文本刊更多论文

老年癌症患者虚弱的血液生物标志物。

综述目的：本综述旨在评估目前基于血液的生物标志物在老年癌症患者虚弱检测中的证据。它探讨了各种生物标志物的潜力，包括炎症标志物和microRNAs (miRNAs)，作为虚弱的指标，并检查了现有研究的局限性。该综述还强调了进一步研究以验证这些生物标志物并提高其临床适用性的必要性。最近的发现：最近的研究已经检查了与老年癌症患者虚弱相关的血液生物标志物。研究结果表明，粒细胞水平升高和巨噬细胞来源的干细胞和调节性T细胞降低与虚弱有关。炎症生物标志物，如白细胞介素-6和特异性mirna，以及较高的中性粒细胞与淋巴细胞比率，也被确定为虚弱的潜在指标。虽然这些生物标记物显示出希望，但没有一种标记物被证明是足够的，将它们结合起来可能会改善虚弱的检测。需要进一步的研究来验证它们在这一人群中的临床应用。摘要：基于血液的生物标志物显示出检测老年癌症患者虚弱的潜力，但需要进一步的研究，特别是超越炎症焦点和更强大的研究设计。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Supportive and Palliative Care HEALTH CARE SCIENCES & SERVICES-

CiteScore

3.70

自引率

0.00%

发文量

期刊介绍： A reader-friendly resource, Current Opinion in Supportive and Palliative Care provides an up-to-date account of the most important advances in the field of supportive and palliative care. Each issue contains either two or three sections delivering a diverse and comprehensive coverage of all the key issues, including end-of-life management, gastrointestinal systems and respiratory problems. Current Opinion in Supportive and Palliative Care is an indispensable journal for the busy clinician, researcher or student.